TREM2 Data Surprise at SfN Annual Meeting
Protein touted as a peripheral monocyte receptor that worsens amyloid plaque pathology in transgenic mice.
ALL NEWS
6572 RESULTS
Sort By:
- Most Recent
- Most Commented
Helper Drug Boosts Response to Riluzole in ALS Mice
Medication blocks molecular transporters that eject riluzole from the nervous system.
Meet GE180: A PET Ligand for Tracking Neuroinflammation?
After lighting up microglia in mouse models of AD, a tracer is headed for clinical trials.
CTAD Shows Alzheimer’s Field Trying to Reinvent Itself
A sense of change on all fronts pervaded the Clinical Trials on Alzheimer’s Disease conference. Scientists shared their early experiences of what works and what does not as they begin trials with newly defined cohorts, new diagnostic criteria, and new outcomes.
Clinical Trials on Alzheimer’s Disease 2014
CTAD Shows Alzheimer’s Field Trying to Reinvent Itself Rusty Unleashed: Forget Disease Modification, Go for Big Effect From Shared CAP, Secondary Prevention Trials Are Off and Running Immunotherapy I: Baby Steps, but No Breakthroughs Immunotherapy II: Act
Exosomes: The FedEx of the Nervous System?
Tiny secreted vesicles emerge as important players in communication between brain cells. Are they important in neurodegeneration?
TDP-43 Structure Reveals Two-Faced Amino End
The amino terminus toggles between a neatly folded nucleic acid-binding domain and a disorganized configuration that forms inclusions.
Exosomes: Purveyors of Neurodegenerative Disease?
A new trend in cell biology points to vesicles released from cells as agents that form and spread pathogenic proteins.
Hats Off to ApoE—Key to Formation of Functional Amyloid
Lipoprotein cap on pigment cell exosomes is essential for production of an amyloid scaffold that concentrates melanin.
Rusty Unleashed: Forget Disease Modification, Go for Big Effect
At CTAD, former FDA neurology leader Rusty Katz urged Alzheimer’s trialists to stop fussing over disease progression. He recommended going after a large effect, regardless of whether it can garner a label of disease modification. That, he says, may mean combination trials.
From Shared CAP, Secondary Prevention Trials Are Off and Running
A CAP symposium opened the CTAD conference, indicating that presymptomatic treatment and “federated” research have become mainstream thinking in Alzheimer’s therapy development. EPAD is pulling together European sites.
Immunotherapy I: Baby Steps, but No Breakthroughs
Researchers at CTAD reported seeing biomarkers budge in active and passive immunotherapy trials, but measurement techniques and screening protocols still need improvement for early stage trials to succeed.
Immunotherapy II: Active Approaches Down, New Passive Crops Up
Researchers at CTAD announced the end for two active immunotherapies, along with the curious story of a placebo as a treatment and the start of a new antibody.
Scientists Seek, Find, and Exploit AD Risk Genes
Using creative ways of mining genetic data, researchers are coming up with new risk variants for Alzheimer’s.
Mouse with Endogenous SOD1 Mutation: A New Model of Early ALS?
Chemical mutagenesis yields an SOD1 variant found in people with the disease. Neurons degenerate without overexpression of the enzyme.
Current Filters
No filters selected